Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study.
Akihito KawazoeDaisuke KotaniYoshiaki NakamuraAkihito KawazoeYasutoshi KubokiKohei ShitaraTakashi KojimaHiroya TaniguchiJun WatanabeItaru EndoTakayuki YoshinoPublished in: Therapeutic advances in medical oncology (2021)
Our study shows that OS and PFS are longer in patients treated with TAS102 plus BEV than in those treated with TAS102 or regorafenib monotherapy.